RECOVER-SLEEP: Platform Protocol

Launched by DUKE UNIVERSITY · May 6, 2024

Keywords

ClinConnect Summary

The RECOVER-SLEEP trial is a research study that aims to find out how different treatments can help people who are experiencing sleep problems after having COVID-19, also known as Long COVID. Specifically, it focuses on issues like excessive daytime sleepiness (hypersomnia) and other sleep disturbances that can occur after infection. The trial is looking for adults aged 18 and older who have had confirmed or suspected COVID-19 and are facing new or worsening sleep issues for at least 12 weeks.

Participants in the study will undergo assessments to understand their sleep problems better and may receive one of several different treatments aimed at improving their sleep. To take part, individuals must not be currently infected with COVID-19 and should not have certain medical conditions that could affect their participation. If eligible, participants can expect to complete surveys and attend follow-up visits to monitor their progress. This study is important as it seeks to improve the quality of life for those suffering from sleep issues related to Long COVID.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• • 1. ≥ 18 years of age at the time of enrollment
• 2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization:
• Suspected\* case of SARS-CoV-2 infection - Three options, A through C:
• A. Met the clinical OR epidemiological criteria:
• • 1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia;
• • 2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presented with acute respiratory infection with a history of fever or measured fever of ≥ 38°C and cough, with onset within the last 10 days, and required hospitalization; or C. Presented with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
• • Probable\* case of SARS-CoV-2 infection, defined as having met the clinical criteria above AND was a contact of a probable or confirmed case or is linked to a COVID-19 cluster; or
• Confirmed case of SARS-CoV-2 infection - Two options, A through B:
• • A. Presented with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Met clinical criteria AND/OR epidemiological criteria (See suspected case A), with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
• • \* Suspected and probable cases will only be allowed if they occurred before May 1, 2021, and will be limited to 10% of the study population. Otherwise, confirmed cases are required.
• • 3. New/worse sleep problems following a SARS-CoV-2 infection that have persisted for at least 12 weeks and are still present at the time of consent
• • 4. PROMIS 8a SRI or 8b SD T Score ≥ 55\*\*
• • \*\* Screening with both the PROMIS 8a SRI and 8b SD will occur for the phenotype assessment portion of the protocol.
• • 5. Willing and able to provide informed consent, complete the surveys and clinical assessments, and return for all of the necessary follow-up visits
• • 6. Adequate method of birth control for participants of child-bearing potential
• Exclusion Criteria:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent
• • 2. Known pregnancy, breastfeeding, or contemplating pregnancy during the study period
• • 3. Untreated sleep apnea (AHI ≥ 15 or severe sleep-related hypoxemia)
• • 4. Current night or rotating shift work
• • 5. Known history of narcolepsy prior to SARS-CoV-2 infection
• • 6. Any non-marijuana illicit drug use within 30 days of informed consent
• • 7. Known history of severe mental disorder, such as psychotic disorders and bipolar disorder
• • 8. Current or recent use (within the last 14 days) of study intervention or similar intervention to treat the underlying condition, unless a washout period is permitted per appendix\*
• • 9. Known allergy/sensitivity or any hypersensitivity to components of the study intervention or control\*
• • 10. Known contraindication(s) to study intervention including prohibited concomitant medications and without the ability to safely hold prohibited concomitant medications (see appendices)\*
• • 11. Currently receiving/using intervention from another clinical trial that could impact or mask treatment effect; refer to MOP for details
• • 12. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study
• • (\*)If only one study intervention appendix is open at the time of enrollment. If multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity yet remain eligible for the remaining study intervention appendices.